Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.69 |
| ▸ | TNF | P01375 | 5/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.65 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | MUSK | O15146 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | RAF1 | P04049 | 1/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.65 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.65 |
| ▸ | PRKCB | P05771 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619149 | 0.91 | MAPK14 (0.78) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5619010 | 0.90 | MAPK14 (0.67) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6249544 | 0.88 | MAPK14 (0.83) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6165706 | 0.87 | MAPK14 (0.71) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5374159 | 0.84 | MAPK14 (0.62) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL1600543 | 0.83 | MAPK14 (0.71) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5619447 | 0.83 | MAPK14 (0.63) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6546393 | 0.82 | MAPK14 (0.80) | MAPK14ABL1EGFRRAF1LCK | |
| SCHEMBL1599504 | 0.82 | MAPK14 (0.82) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL29593532 | 0.82 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6492393-B1 | SUCH AS 1-(5-TERT-BUTYL-2-METHOXYPHENYL)-3-(4-(2-METHOXY-PYRIDIN-4YL-OXY)-NAPHTHALEN-1-YL)-UREA; CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | EPX, MPO, RELA | MAPK14 3716/4885TNF 15/4885MAPK13 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.